Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Alzheimer's Disease

  Free Subscription


Articles published in Lancet Neurol

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    October 2018
  1. BALIN BJ, Hudson AP
    Herpes viruses and Alzheimer's disease: new evidence in the debate.
    Lancet Neurol. 2018;17:839-841.
    PubMed     Text format    


    August 2018
  2. FORTEA J, Carmona-Iragui M, Benejam B, Fernandez S, et al
    Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30285.
    PubMed     Text format     Abstract available


  3. RAFII MS
    Diagnostic biomarkers of Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30293.
    PubMed     Text format    


  4. CARMONA S, Zahs K, Wu E, Dakin K, et al
    The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders.
    Lancet Neurol. 2018;17:721-730.
    PubMed     Text format     Abstract available


    June 2018
  5. KNUDSEN K, Fedorova TD, Hansen AK, Sommerauer M, et al
    In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Lancet Neurol. 2018 Jun 1. pii: S1474-4422(18)30162.
    PubMed     Text format     Abstract available


    May 2018
  6. DUFOUIL C, Glymour MM
    Prediction to prevention in Alzheimer's disease and dementia.
    Lancet Neurol. 2018;17:388-389.
    PubMed     Text format    


    March 2018
  7. VAN DER LEE SJ, Wolters FJ, Ikram MK, Hofman A, et al
    The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.
    Lancet Neurol. 2018 Mar 16. pii: S1474-4422(18)30053.
    PubMed     Text format     Abstract available


  8. BALLARD C, Banister C, Khan Z, Cummings J, et al
    Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Lancet Neurol. 2018;17:213-222.
    PubMed     Text format     Abstract available


  9. SCHNEIDER LS
    Pimavanserin for patients with Alzheimer's disease psychosis.
    Lancet Neurol. 2018;17:194-195.
    PubMed     Text format    


    February 2018
  10. DUBOIS B, Epelbaum S, Nyasse F, Bakardjian H, et al
    Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Lancet Neurol. 2018 Feb 27. pii: S1474-4422(18)30029.
    PubMed     Text format     Abstract available


  11. WESTON PSJ, Nicholas JM, Henley SMD, Liang Y, et al
    Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2018;17:123-132.
    PubMed     Text format     Abstract available


  12. REIMAN EM
    Long-term forgetting in preclinical Alzheimer's disease.
    Lancet Neurol. 2018;17:104-105.
    PubMed     Text format    


    January 2018
  13. GORDON BA, Blazey TM, Su Y, Hari-Raj A, et al
    Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30028.
    PubMed     Text format     Abstract available


  14. TIJMS BM, Visser PJ
    Capturing the Alzheimer's disease pathological cascade.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30043.
    PubMed     Text format    


  15. AUGUSTIN K, Khabbush A, Williams S, Eaton S, et al
    Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.
    Lancet Neurol. 2018;17:84-93.
    PubMed     Text format     Abstract available


    December 2017
  16. THE LANCET NEUROLOGY
    Alzheimer's disease: evolution of research diagnostic criteria.
    Lancet Neurol. 2017;16:945.
    PubMed     Text format    


    November 2017
  17. HALLIDAY G
    Pathology and hippocampal atrophy in Alzheimer's disease.
    Lancet Neurol. 2017;16:862-864.
    PubMed     Text format    


    October 2017
  18. SOININEN H, Solomon A, Visser PJ, Hendrix SB, et al
    24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30332.
    PubMed     Text format     Abstract available


  19. YASSINE HN
    Targeting prodromal Alzheimer's disease: too late for prevention?
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30372.
    PubMed     Text format    


    September 2017
  20. JOSEPHS KA, Dickson DW, Tosakulwong N, Weigand SD, et al
    Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Lancet Neurol. 2017 Sep 11. pii: S1474-4422(17)30284.
    PubMed     Text format     Abstract available


  21. DROUIN E, Drouin G
    The first report of Alzheimer's disease.
    Lancet Neurol. 2017;16:687.
    PubMed     Text format    


    August 2017
  22. FRISONI GB, Boccardi M, Barkhof F, Blennow K, et al
    Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
    Lancet Neurol. 2017;16:661-676.
    PubMed     Text format     Abstract available


  23. COLEY N, Andrieu S
    Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply.
    Lancet Neurol. 2017;16:586.
    PubMed     Text format    


  24. YASSINE HN, Schneider LS
    Lessons from the Multidomain Alzheimer Preventive Trial.
    Lancet Neurol. 2017;16:585-586.
    PubMed     Text format    


  25. ESCOTT-PRICE V, Jones L
    Genomic profiling and diagnostic biomarkers in Alzheimer's disease.
    Lancet Neurol. 2017;16:582-583.
    PubMed     Text format    


  26. ISAAC MT, Vamvakas S, Isaac MB
    Diagnostic biomarkers for Alzheimer's disease: a regulatory view.
    Lancet Neurol. 2017;16:580-581.
    PubMed     Text format    


    June 2017
  27. KIRBY T
    Eric Reiman: aiming to prevent Alzheimer's disease.
    Lancet Neurol. 2017 Jun 30. pii: S1474-4422(17)30216.
    PubMed     Text format    


    May 2017
  28. HARDY J
    Membrane damage is at the core of Alzheimer's disease.
    Lancet Neurol. 2017;16:342.
    PubMed     Text format    


    April 2017
  29. VOSSEL KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al
    Epileptic activity in Alzheimer's disease: causes and clinical relevance.
    Lancet Neurol. 2017;16:311-322.
    PubMed     Text format     Abstract available


    February 2017
  30. THE LANCET NEUROLOGY
    Solanezumab: too late in mild Alzheimer's disease?
    Lancet Neurol. 2017;16:97.
    PubMed     Text format    


    January 2017
  31. SCHNEIDER L
    Alzheimer's disease and other dementias: update on research.
    Lancet Neurol. 2017;16:4-5.
    PubMed     Text format    


  32. ATTEMS J
    Alzheimer's disease pathology in synucleinopathies.
    Lancet Neurol. 2017;16:22-23.
    PubMed     Text format    


  33. IRWIN DJ, Grossman M, Weintraub D, Hurtig HI, et al
    Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Lancet Neurol. 2017;16:55-65.
    PubMed     Text format     Abstract available


    December 2016
  34. PANZA F, Logroscino G
    Anti-tau vaccine in Alzheimer's disease: a tentative step.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30340.
    PubMed     Text format    


  35. NOVAK P, Schmidt R, Kontsekova E, Zilka N, et al
    Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30331.
    PubMed     Text format     Abstract available


    October 2016
  36. RYAN NS, Nicholas JM, Weston PS, Liang Y, et al
    Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30193.
    PubMed     Text format     Abstract available


  37. VAN DER FLIER WM
    Clinical heterogeneity in familial Alzheimer's disease.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30275.
    PubMed     Text format    


  38. TANG M, Ryman DC, McDade E, Jasielec MS, et al
    Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30229.
    PubMed     Text format     Abstract available


    August 2016
  39. MORGAN J
    An orange and Alzheimer's disease?
    Lancet Neurol. 2016;15:911.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: